Winners and losers from Medicare pricing negotiation plans; devicemaker sues rival alleging theft of trade secrets

Taking stock of the drug industry, from the lab to the medicine chest

August 29, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Anna Moneymaker/Getty Images Here are the 10 drugs that will be up first for Medicare price negotiation Medicare has announced the first 10 medicines that will be up first in its new drug price negotiation program. By Rachel Cohrs and Matthew Herper STAT+ | Winners and losers from Medicare's list of drugs subject to price negotiation Naming 10 medicines to the Medicare drug price negotiation list is a milestone, and a point to start appraising the impact of the process. By Matthew Herper and Damian Garde STAT+ | As competition looms, Insulet sues a rival for allegedly stealing trade secrets on diabetes tech Insulet filed a lawsuit this month against EOFlow for stealing trade secrets in a case that could shake up the diabetes tech market. By Lizzy Lawrence Drew Angerer/Getty Images Opinion: Every senator should fill out a legislative advance directive Legislative advance directives that senators could complete before the start of each term might be a remedy to recent alarming moments. By Joseph J. Fins

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser